Positive News SentimentPositive NewsNASDAQ:KROS Keros Therapeutics (KROS) Stock Forecast, Price & News $30.82 -1.06 (-3.32%) (As of 10/2/2023 ET) Add Compare Share Share Today's Range$30.57▼$33.0850-Day Range$31.57▼$43.0152-Week Range$30.57▼$59.96Volume294,439 shsAverage Volume209,583 shsMarket Capitalization$914.12 millionP/E RatioN/ADividend YieldN/APrice Target$94.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Keros Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside206.1% Upside$94.33 Price TargetShort InterestBearish5.60% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.84Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.25) to ($5.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.15 out of 5 starsMedical Sector484th out of 969 stocksPharmaceutical Preparations Industry223rd out of 452 stocks 3.5 Analyst's Opinion Consensus RatingKeros Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $94.33, Keros Therapeutics has a forecasted upside of 206.1% from its current price of $30.82.Amount of Analyst CoverageKeros Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.60% of the float of Keros Therapeutics has been sold short.Short Interest Ratio / Days to CoverKeros Therapeutics has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Keros Therapeutics has recently increased by 3.51%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldKeros Therapeutics does not currently pay a dividend.Dividend GrowthKeros Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KROS. Previous Next 3.2 News and Social Media Coverage News SentimentKeros Therapeutics has a news sentiment score of 1.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Keros Therapeutics this week, compared to 1 article on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Keros Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders28.00% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.56% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Keros Therapeutics are expected to grow in the coming year, from ($5.25) to ($5.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Keros Therapeutics is -6.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Keros Therapeutics is -6.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKeros Therapeutics has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Keros Therapeutics (NASDAQ:KROS) StockKeros Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical need in the United States. The company's lead protein therapeutic product candidate KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-047, a small molecule product candidate that is in Phase II clinical trials for the treatment of functional iron deficiency; and KER-012, which is in Phase II clinical trials to treat pulmonary arterial hypertension and cardiovascular disorders. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Read More KROS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KROS Stock News HeadlinesAugust 31, 2023 | markets.businessinsider.comWedbush Sticks to Their Buy Rating for Keros Therapeutics (KROS)August 20, 2023 | nasdaq.comBenjamin Graham Detailed Fundamental Analysis - KROSOctober 2, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>August 9, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Cigna (CI), Keros Therapeutics (KROS) and Qiagen (QGEN)August 9, 2023 | markets.businessinsider.comTruist Financial Remains a Buy on Keros Therapeutics (KROS)August 8, 2023 | msn.comWedbush Reiterates Keros Therapeutics (KROS) Outperform RecommendationAugust 8, 2023 | finanznachrichten.deKeros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial ResultsAugust 8, 2023 | markets.businessinsider.comWedbush Sticks to Its Buy Rating for Keros Therapeutics (KROS)October 2, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>August 7, 2023 | finance.yahoo.comKeros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial ResultsAugust 2, 2023 | seekingalpha.comKeros Therapeutics: Hematological Therapies Continue To AdvanceJuly 31, 2023 | markets.businessinsider.comWedbush Initiates a Buy Rating on Keros Therapeutics (KROS)July 27, 2023 | finance.yahoo.comCorrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial HypertensionJuly 26, 2023 | markets.businessinsider.comWhere Keros Therapeutics Stands With AnalystsJuly 24, 2023 | finance.yahoo.comKeros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial HypertensionJuly 23, 2023 | fool.comKeros Therapeutics (NASDAQ: KROS)June 12, 2023 | finance.yahoo.comKeros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare ConferenceJune 9, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Keros Therapeutics (KROS)June 9, 2023 | finance.yahoo.comKeros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology AssociationJune 7, 2023 | finance.yahoo.comKeros Therapeutics to Present at Goldman Sach’s 44th Annual Global Healthcare ConferenceMay 29, 2023 | markets.businessinsider.comKeros Therapeutics (KROS) Receives a Rating Update from a Top AnalystMay 23, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Rain Therapeutics (RAIN) and Keros Therapeutics (KROS)May 22, 2023 | finance.yahoo.comKeros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International ConferenceMay 11, 2023 | finance.yahoo.comKeros Therapeutics to Present at the 28th Annual Congress of the European Hematology AssociationMay 9, 2023 | msn.comHC Wainwright & Co. Reiterates Keros Therapeutics (KROS) Buy RecommendationMay 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Karuna Therapeutics (KRTX) and Keros Therapeutics (KROS)May 7, 2023 | seekingalpha.comKeros Therapeutics GAAP EPS of -$1.26See More Headlines Receive KROS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KROS Company Calendar Last Earnings8/07/2023Today10/02/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KROS CUSIPN/A CIK1664710 Webwww.kerostx.com Phone617-314-6297FaxN/AEmployees121Year FoundedN/APrice Target and Rating Average Stock Price Forecast$94.33 High Stock Price Forecast$110.00 Low Stock Price Forecast$65.00 Forecasted Upside/Downside+206.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,680,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.19% Return on Assets-38.93% Debt Debt-to-Equity RatioN/A Current Ratio20.77 Quick Ratio20.77 Sales & Book Value Annual Sales$20.10 million Price / Sales45.48 Cash FlowN/A Price / Cash FlowN/A Book Value$10.07 per share Price / Book3.06Miscellaneous Outstanding Shares29,660,000Free Float21,357,000Market Cap$914.12 million OptionableNot Optionable Beta1.16 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Jasbir S. Seehra Ph.D. (Age 67)Pres, CEO, Treasurer, & Director Comp: $985.58kMr. Christopher Rovaldi M.Sc. (Age 49)Chief Operating Officer Comp: $708.75kDr. Simon Cooper MBBS (Age 53)Chief Medical Officer Comp: $654.27kMr. Keith C. Regnante MBA (Age 53)Chief Financial Officer Ms. Esther Cho J.D.Sr. VP, Gen. Counsel & Sec.Ms. Robin WagnerVP of HRDr. Jennifer Lachey Ph.D. (Age 50)Sr. VP of Discovery Mr. John Oram M.B.A.Sr. VP of Program & Portfolio ManagementMore ExecutivesKey CompetitorsDeciphera PharmaceuticalsNASDAQ:DCPHAcelyrinNASDAQ:SLRNPliant TherapeuticsNASDAQ:PLRXAvadel PharmaceuticalsNASDAQ:AVDLArdelyxNASDAQ:ARDXView All CompetitorsInsiders & InstitutionsCHI Advisors LLCBought 141,059 shares on 8/22/2023Ownership: 1.356%California State Teachers Retirement SystemBought 3,388 shares on 8/21/2023Ownership: 0.084%Osaic Holdings Inc.Bought 884 shares on 8/21/2023Ownership: 0.003%Nuveen Asset Management LLCSold 15,510 shares on 8/16/2023Ownership: 0.174%Citadel Advisors LLCBought 400 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions KROS Stock - Frequently Asked Questions Should I buy or sell Keros Therapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Keros Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KROS shares. View KROS analyst ratings or view top-rated stocks. What is Keros Therapeutics' stock price forecast for 2023? 7 Wall Street analysts have issued 1 year target prices for Keros Therapeutics' stock. Their KROS share price forecasts range from $65.00 to $110.00. On average, they expect the company's share price to reach $94.33 in the next year. This suggests a possible upside of 206.1% from the stock's current price. View analysts price targets for KROS or view top-rated stocks among Wall Street analysts. How have KROS shares performed in 2023? Keros Therapeutics' stock was trading at $48.02 on January 1st, 2023. Since then, KROS stock has decreased by 35.8% and is now trading at $30.82. View the best growth stocks for 2023 here. When is Keros Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our KROS earnings forecast. How were Keros Therapeutics' earnings last quarter? Keros Therapeutics, Inc. (NASDAQ:KROS) announced its earnings results on Monday, August, 7th. The company reported ($1.27) EPS for the quarter, beating analysts' consensus estimates of ($1.34) by $0.07. During the same quarter in the prior year, the business posted ($1.13) earnings per share. What ETFs hold Keros Therapeutics' stock? ETFs with the largest weight of Keros Therapeutics (NASDAQ:KROS) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and ALPS Medical Breakthroughs ETF (SBIO).BNY Mellon Innovators ETF (BKIV). What other stocks do shareholders of Keros Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Keros Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Cloudera (CLDR), CVS Health (CVS), Inovio Pharmaceuticals (INO), Iovance Biotherapeutics (IOVA), Karyopharm Therapeutics (KPTI), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Pfizer (PFE). When did Keros Therapeutics IPO? (KROS) raised $75 million in an initial public offering (IPO) on Wednesday, April 8th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. What is Keros Therapeutics' stock symbol? Keros Therapeutics trades on the NASDAQ under the ticker symbol "KROS." How do I buy shares of Keros Therapeutics? Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Keros Therapeutics' stock price today? One share of KROS stock can currently be purchased for approximately $30.82. How much money does Keros Therapeutics make? Keros Therapeutics (NASDAQ:KROS) has a market capitalization of $914.12 million and generates $20.10 million in revenue each year. The company earns $-104,680,000.00 in net income (profit) each year or ($4.54) on an earnings per share basis. How many employees does Keros Therapeutics have? The company employs 121 workers across the globe. How can I contact Keros Therapeutics? Keros Therapeutics' mailing address is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. The official website for the company is www.kerostx.com. The company can be reached via phone at 617-314-6297 or via email at jbalanova@troutgroup.com. This page (NASDAQ:KROS) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.